PC
TTPH

Passport Capital’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Passport Capital’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-872
Closed -$190K – 266
2014
Q1 		$190K Buy
+872
New +$243K 0.01% 165

Other funds holding TTPH

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Passport Capital's TTPH Position: Q2 2014 in Review

Passport Capital sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2014, closing a stake of 872 shares — an estimated $190K sold.

Passport Capital first reported a position in TTPH in Q1 2014 and held it in 1 quarter. The position peaked at $190K in Q1 2014. 64 funds tracked by Wall St. Rank hold TTPH as of Q2 2014.

  • Passport Capital reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Passport Capital sold 872 Tetraphase Pharmaceuticals, Inc. shares in Q2 2014, an estimated $190K.
  • Passport Capital first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Passport Capital's Tetraphase Pharmaceuticals, Inc. position peaked at $190K in Q1 2014.
  • 64 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.